Proprietary Subcutaneous Delivery
System and Drug Formulations

Changing the Treatment Paradigm

Administer Parenteral Therapies Outside the Hospital Without an IV

Transforming Patient Care and Reducing Healthcare Costs Through Innovative Subcutaneous Delivery of Proven Drugs for Heart Failure and Infectious Disease

Heart Failure

Subcutaneous administration of furosemide.

Infectious Disease

Subcutaneous delivery of antibiotics.

News

Go to News & Events
4/26/17

John Tucker Appointed as Chief Executive Officer of scPharmaceuticals

FOR IMMEDIATE RELEASE: LEXINGTON, MA., —scPharmaceuticals, Inc., a privately held biopharmaceutical company transforming patient care and healthcare costs through innovative subcutaneous drug delivery, today announced the appointment of John Tucker as president and chief executive officer, effective immediately.

1/24/17

scPharmaceuticals Announces Start of SUBQ-HF NHLBI Study with Its Subcutaneous Furosemide Product

FOR IMMEDIATE RELEASE: LEXINGTON, MA., —scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today the start of the first phase of a study conducted by the Heart Failure Clinical Research Network (HFN).

1/4/17

scPharmaceuticals Announces Closing of $45.6 Million in Series B Financing

FOR IMMEDIATE RELEASE: LEXINGTON, MA. — scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery announced today that it has closed a $45.6 million Series B investment round.